Pharmaceutical manufacturers of Simvastatin

TAPI stands as the primary global provider of active pharmaceutical ingredients (APIs). With the most extensive range of over 370 high-caliber API products in the industry, we cater to almost 1,000 clients across more than 100 nations. Operating as an independent division under Teva Pharmaceutical Industries, our legacy in the generic API sector spans over 80 years. Situated in close proximity to Tel Aviv, Israel, TAPI boasts a workforce of over 5,000 professionals spread across 19 facilities worldwide. Our cutting-edge manufacturing plants are situated in Italy, Hungary, the Czech Republic, Croatia, Israel, India, China, Mexico, and several other locations.

Founded in 1986 by Mr. P. V. Ramprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals, Aurobindo Pharma was born of a vision. The company commenced operations in 1988-89 with a single unit manufacturing Semi-Synthetic Penicillin (SSP) at Pondicherry. Aurobindo Pharma became a public company in 1992 and listed its shares on the Indian stock exchanges in 1995. In addition to being the market leader in Semi-Synthetic Penicillins, it has a presence in key therapeutic segments such as neurosciences, cardiovascular, anti-retrovirals, anti-diabetics, gastroenterology and anti-biotics, among others.

Headquartered in Mumbai, India, Lupin is a global pharmaceutical leader with a footprint across the U.S., LATAM, APAC, EMEA and India, with products distributed in over 100 markets. With a diverse portfolio of over 1,200 products, Lupin remains committed to its mission of making quality healthcare accessible to the communities we serve. Our visionary Founder, Dr. Desh Bandhu Gupta, instilled in us the importance of offering quality, affordable and innovative medicines and being a responsible corporate citizen, making a positive difference to patients, communities and the environment.

Our objective is to pave the path to a more wholesome future. However, we are also concerned about the manner in which we collectively achieve this goal. Being a company whose products impact the well-being of individuals worldwide, we uphold ourselves to a stringent standard and anticipate others to treat us likewise. We are advocates of transparent, truthful, and principled operation with the utmost level of ethics and honesty. This encompasses ensuring the company's compliance with all relevant laws and regulations on a global scale.

Founded in 1978, Biocon Limited is the largest biotechnology company in India and a leading company in Asia, focusing on biopharmaceuticals and research services. It is an integrated and innovation-driven enterprise that provides affordable solutions for chronic diseases globally. The company develops, manufactures, and offers a diverse portfolio of Small Molecules APIs & Formulations and Complex Biologics, including Novels and Biosimilars like MAbs, rh-insulin& Insulin Analogs. Among its notable products are the world's first Pichia-based recombinant human Insulin, INSUGEN, Glargine, BASALOG, and India's first biologic BioMAb-EGFR for head and neck cancer. Additionally, it has developed Itolizumab, a 'first in class' anti-CD6 monoclonal antibody, introduced as Alzumab for psoriasis in India in 2013.

Founded in 1956, Zhejiang Hisun Pharmaceutical Co., Ltd. is a comprehensive pharmaceutical enterprise featuring whole chain, multi-regional integration of research, production and marketing as well as development of drug substances and preparations. In 2000, an A-share was issued in order to enter the stock market as a state-owned listed company. As of 2021, Hisun Pharmaceutical is now one of the largest producers of antibiotics and anti-tumor drugs in China and has been listed in the Top 500 Chinese manufacturing enterprises and the Top 100 Chinese pharmaceutical enterprises multiple times. In 2020 Hisun Pharmaceuticals received special recognition from the Joint Prevention and Control Team from the State Council of the People’s Republic of China for their extraordinary efforts in the fight against the epidemic, and Hisun Pharmaceutical was awarded with the “Anti COVID-19 Advanced Collective in Ministry of Industry and Information Technology".

Greetings, we are Sandoz B2B. As a division of Sandoz, we are completely dedicated to ensuring availability of cost-effective medication for everyone. We distribute high-quality medication globally through close collaboration with pharmaceutical partners. Whether it involves active pharmaceutical ingredients, finished dosage products, or comprehensive end-to-end CDMO solutions, we are here for you.

We are a global vertically integrated pharmaceutical company engaged in research and development, manufacture, sale and distribution of prescription and OTC pharmaceutical products, with global presence in more than 50 countries, including United States, Europe, Canada, Japan, Australia and Rest of the World. We offer a wide range of proprietary finished dosage formulation catering to different therapeutic segments, including CVS, CNS, gastro-intestinal, etc. in multiple dosage forms including: Immediate-release oral solids Modified release oral solids MUPS based products Chewable tablets Powder for oral solutions & Suspensions

Hovione brings over six decades of experience as a CDMO and serves as a specialized integrated provider delivering solutions for drug substance, drug product intermediate, and drug product. With four FDA examined facilities in the United States, China, Ireland, and Portugal, as well as research laboratories in Portugal and the United States, the company supplies pharmaceutical customers with services for the development and compliant production of innovative drugs, including highly potent compounds. Hovione delivers a comprehensive range of development services and manufacturing capabilities in particle engineering such as Spray Drying.

Rochem International, Inc. has been a prominent distributor of pharmaceutical, food, nutritional, and animal health ingredients since its establishment in 1994. It procures top-notch ingredients produced in China. With its headquarters in Hauppauge, New York, Rochem operates 16 global offices to meet its clients' requirements. The company's activities adhere to cGMP standards and have undergone audits by the USFDA and various multinational entities. Furthermore, it provides training and conducts audits for its partners to ensure FDA compliance for their technologies and systems.

Concord Biotech Limited is a prominent vertically integrated, research and development-driven biotechnological powerhouse that produces Active Pharmaceutical Ingredients using fermentation and semi-synthetic methods, as well as Finished formulations. Established in 2000, Concord has evolved from a single-product enterprise to a wide-ranging solution provider, offering products across varied therapeutic segments. Concord is internationally recognized for its products and holds a strong presence in over 50 countries worldwide with effective distribution infrastructure in markets such as North America, Europe, Japan, Central & Latin America, Africa, Australia, and other regions.

Apeloa Pharmaceutical Co., Ltd. is a major high-tech enterprise at the state level and a significant player in the pharmaceutical industry in Zhejiang Province. Our company focuses on the exploration, production, and marketing of pharmaceutical goods, primarily specializing in crude drug (API), contract R & D, production service (CDMO), and preparation (FDF) operations. Our product range is predominantly focused on cardio-cerebrovascular, anti-infection, anti-tumor, and other medical treatment areas. Currently, we produce over 70 types of raw materials on a large scale, with 11 of them exceeding 100 million in sales.

Daewoong Bio Inc., a standalone affiliate of the Daewoong Group located in Seoul, South Korea, was established in 1983. Daewoong Bio manufactures world-class products that comply with cGMP standards under quality assurance systems. As a primary producer, Daewoong Bio supplies APIs for worldwide distribution and multinational enterprises developing innovative products. Daewoong Bio is also a comprehensive pharmaceutical company that employs its internal research and development, production facilities, and experienced marketing team along with external global connections. Daewoong Bio specializes in the production of top-notch antibiotic APIs and general APIs.

HELM AG, a company based in Hamburg and owned by a family, has a 120-year history in 4 diverse sectors: Pharmaceuticals, Chemicals, Crop Protection, and Crop Nutrition. With a global presence through subsidiaries, sales offices, and partnerships, HELM is recognized as one of the world's leading independent marketing firms for chemicals. At HELM Pharma, our goal is to establish ourselves as the top B2B project and marketing platform, offering a distinctive partnership experience. In the marketing of our products, we deliver a comprehensive range of services for our business associates.

Anuh Pharma Ltd., a Bulk Drugs Manufacturing Company is part of the INR 8.5 bn SK Group of Companies, which employs 2000+ people across businesses such as Manufacturing of API's, Pharma Formulations, Distribution and Logistics. Established in 1960, Anuh Pharma Ltd. today is one of the largest manufacturers of Macrolides and Anti-TB products in India, besides being a major player in Anti-Bacterials, Anti-Malarial, and Corticosteroids.

Zhejiang Jingxin Pharmaceutical Co., Ltd. was established in 1990. It is a listed pharmaceutical company integrating R&D, production and sales. Following the business policy of "strengthening the main business of pharmaceuticals and developing medical devices", adhering to the core values ​​of "pragmatism, innovation, tolerance and win-win", and taking "carefully protecting health" as its mission, it is committed to becoming a leader in the fields of Chinese psychiatric, neurological, cardiovascular and cerebrovascular diseases...

Zhejiang Jiangbei Pharmaceutical Co., LTD., founded in July 1993, is an integrated and international pharmaceutical enterprise mainly engaged in pharmaceutical preparations, APIs and intermediates.It is honored as a national high-tech enterprise, a top 100 pharmaceutical international enterprise, a science and technology enterprise in Zhejiang Province, a key pharmaceutical enterprise in Taizhou City, a company planning to be listed in Taizhou City, a meritorious enterprise in Jiaojiang District, ranked third in Jiaojiang District's enterprise in the level of tax payment above 100 million yuan in 2022. It has 2 subsidiaries, i.e. an API and intermediate manufacturing company (Zhejiang Jiangbei Nanhai Pharmaceutical Co., Ltd.) and a trading company (Zhejiang Jiangbei Hongrui Import and Export Co., Ltd.). The company has a good product group, the formation of cardiovascular, antiviral, central nervous, digestive tract, anti-infection, anti-coagulation, anti-osteoporosis, from intermediates, APIs to solid preparations. A set of quality management system with high standards, strict requirements, continuous improvement has been established. At present, API products like Simvastatin, Atorvastatin Calcium, Levetiracetam have passed the authority inspection or certification of the US FDA, the EU CEP, WHO, the UK, Russia, Japan, South Korea, India, etc. The preparation products have also passed the inspection or certification of WHO and MHRA.